Institut de Cancérologie de l'Ouest (ICO)

Name

Institut de Cancérologie de l'Ouest (ICO)

Legal name

Institut de Cancérologie de l'Ouest

Website

https://institut-cancerologie-ouest.com

Company type

Private

Founded year

1923

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Cancer Treatment Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310)

SIC

Services-Hospitals (8060), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

akta.pro secondary industry

Academic Medical Centers (AMCs) & Teaching Hospitals (HLAFAAAA)

Keywords

• Cancer treatment services
• Oncology care
• Clinical research
• Radiation therapy
• Medical oncology

Headquarters

HQ city

Angers

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Distribution channels2 records

Marketing channels3 records

Core offering

ICO is a non-profit ESPIC cancer center delivering comprehensive, personalized cancer care across two hospital sites in Angers and Saint-Herblain (Pays de la Loire, France). It provides medical oncology (chemotherapy), surgical oncology, and radiation therapy, complemented by diagnostic imaging, a COFRAC-accredited biopathology laboratory, palliative and supportive care, and prevention programs. It also runs an academic clinical trials program through UNICANCER and a teaching mission for medical and healthcare professionals.

Product overview

The Institut de Cancérologie de l'Ouest (ICO) is a comprehensive cancer center operating as a private health establishment of collective interest (ESPIC) with two sites in Pays de la Loire (Angers and Saint-Herblain). The institution delivers an integrated portfolio of cancer care services structured around four core missions: prevention, care, research, and education. The service portfolio includes medical oncology (chemotherapy), surgical oncology, and radiation therapy as primary treatment modalities, complemented by advanced diagnostic imaging (radiology, nuclear medicine, PET scans), a COFRAC-accredited biopathology laboratory, and palliative/supportive care services. ICO operates an active clinical trials program through the UNICANCER academic research network, providing patients access to experimental therapies. Patient-facing resources include the ONCOALIM nutrition living lab and Les Chroniques Métastatiques podcast. The institution implements patient-reported outcome measures following ICHOM oncology standards. ICO is a member of the UNICANCER federation, which coordinates clinical research, best practices, and mutualized procurement across 18 French cancer centers.

Differentiator

Problem solved

Functional benefit

Products and services

• Cancer Treatment Services Comprehensive cancer treatment including medical oncology (chemotherapy), surgical oncology, and radiation therapy delivered to adult and pediatric patients across two sites in the Pays de la Loire region (Angers and Saint-Herblain).
• Prevention Programs Primary, secondary, and tertiary cancer prevention services encompassing screening, early detection, and prevention of cancer recurrence for the regional population.
• Clinical Trials Program Academic and sponsored clinical research program offering patients access to experimental treatments and novel therapeutic molecules, including Phase 2 studies such as OPALESCENCE (TLX250-CDx in metastatic triple negative breast cancer). ISO 9001:2015-certified for trial design and management.
• Medical Education and Training Teaching and training programs for medical professionals, students, and healthcare practitioners in oncology, aligned with the continuum of care-research-education missions of a Centre de Lutte Contre le Cancer.
• Diagnostic Imaging Services Advanced medical imaging including radiology, nuclear medicine, PET scans, scintigraphy, and stereotactic radiotherapy planning for cancer diagnosis, staging, and treatment planning.
• Palliative and Supportive Care Pain management, palliative care, psychological support, social work services, and quality-of-life optimization for cancer patients, including intrathecal preparations for pain management.
• Biopathology Laboratory Services Medical biology and anatomic pathology diagnostic testing accredited by COFRAC according to NF-EN-ISO 15189 standards, guaranteeing optimal quality of examinations performed for cancer diagnosis and monitoring.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature2 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Telix PharmaceuticalscoreStrategic or Co-development Partner · 11 November 2025ICO participated as a clinical trial site in the Phase 2 OPALESCENCE trial evaluating TLX250-CDx (Zircaix) in metastatic triple negative breast cancer (mTNBC). Results published in the European Journal of Nuclear Medicine and Molecular Imaging demonstrated high sensitivity and tumor detection with no safety issues, confirming theranostic potential.
• UNICANCERcoreStrategic or Co-development PartnerICO is a member of UNICANCER, the only French hospital network 100% dedicated to cancer. UNICANCER comprises 18 Cancer Centers (CLCC) across 20 hospital sites with over 20,000 professionals. It is the leading European academic clinical trial promoter and produces one-third of international oncology publications from France. UNICANCER coordinates national purchasing, represents centers nationally and internationally, and manages collective agreements for center employees.
• RocheminorStrategic or Co-development PartnerRoche supported the ISO 9001:2015 certification initiative for ICO's Clinical Research Department, which covers clinical trial design and management activities.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Gustave Roussy: Largest French comprehensive cancer center and UNICANCER member in Villejuif, combining oncology care, research, and teaching. Directly comparable to ICO as a fellow CLCC offering integrated cancer services at greater scale.
• Institut Curie: Paris-based UNICANCER member operating a hospital and Research Center with a similar care-research-teaching continuum. Directly comparable to ICO in mission, ESPIC-adjacent status, and multidisciplinary oncology portfolio.
• Centre Léon Bérard: Lyon-based UNICANCER CLCC providing comprehensive cancer treatment, research, and education. Directly comparable regional CLCC peer with similar two-site-equivalent structure and academic trial activity.
• Institut Paoli-Calmettes: Marseille-based UNICANCER CLCC delivering medical oncology, surgery, radiotherapy, and translational research. Directly comparable as a regional comprehensive cancer center with the same federated model.
• Institut Bergonié: Bordeaux-based UNICANCER CLCC providing comprehensive cancer care, clinical research, and teaching. Comparable regional CLCC peer with overlapping service lines and federation affiliation.
• Centre François Baclesse: Caen-based UNICANCER CLCC delivering oncology care, radiotherapy, and clinical research in Normandy. Comparable as a regional CLCC peer under the same federation operating model.
• Centre Georges-François Leclerc: Dijon-based UNICANCER CLCC focused on oncology care and research. Comparable regional CLCC peer with similar academic clinical trial participation and integrated service model.
• Centre Jean Perrin: Clermont-Ferrand-based UNICANCER CLCC offering comprehensive oncology services and translational research. Comparable regional CLCC peer under the same federated governance.
• Institut de Cancérologie de Lorraine: Nancy-based UNICANCER CLCC providing cancer care, radiotherapy, and clinical research. Comparable regional CLCC peer with overlapping service portfolio and federation affiliation.

Regional players

• The Royal Marsden NHS Foundation Trust: UK-based specialist oncology hospital and research center with a similar care-research-teaching mission. Comparable in scope and academic oncology profile, but operates under the NHS in a different geography and reimbursement system.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/ICO_cancer
• YouTubeyoutube.com/channel/UCp1mH3YISb6TkHWb5x5lG5Q
• Facebookfacebook.com/institutdecancerologiedelouest
• LinkedInlinkedin.com/company/institut-de-cancerologie-de-louest
• Instagraminstagram.com/institutcancerologieouest

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institut de Cancérologie de l'Ouest (ICO)